<SEC-DOCUMENT>0001193125-18-037945.txt : 20180209
<SEC-HEADER>0001193125-18-037945.hdr.sgml : 20180209
<ACCEPTANCE-DATETIME>20180209160503
ACCESSION NUMBER:		0001193125-18-037945
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180209
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20180209
DATE AS OF CHANGE:		20180209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		18591685

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d451547d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Date of Report (Date of earliest event reported):&nbsp;February&nbsp;9, 2018 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g451547img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">as
Specified in its Charter) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-01011</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><FONT STYLE="white-space:nowrap">05-0494040</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer Identification No.)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>One CVS Drive</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>Woonsocket, Rhode Island</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02895</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Registrant&#146;s telephone number, including area code:&nbsp;<B>(401)
<FONT STYLE="white-space:nowrap">765-1500</FONT></B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined
in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this
chapter). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Emerging growth company &#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The date of the special meeting of stockholders of CVS Health Corporation (&#147;CVS
Health&#148;) to seek the approval by CVS Health&#146;s stockholders of the issuance of shares contemplated under the Agreement and Plan of Merger pursuant to which CVS Health has agreed to acquire Aetna Inc. has been changed to March&nbsp;13, 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to
subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any
jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed transaction between CVS Health Corporation (&#147;CVS Health&#148;) and Aetna Inc. (&#147;Aetna&#148;), on February&nbsp;9,
2018, CVS Health filed with the Securities and Exchange Commission (the &#147;SEC&#148;) an amendment to the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> that was originally filed on January&nbsp;4, 2018. The
registration statement includes a joint proxy statement of CVS Health and Aetna that also constitutes a prospectus of CVS Health. The registration statement was declared effective by the SEC on February&nbsp;9, 2018, and the definitive joint proxy
statement/prospectus of CVS Health and Aetna will be mailed to stockholders of CVS Health and shareholders of Aetna beginning on or about February&nbsp;12, 2018. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE DEFINITIVE
JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the
registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at <U>http://www.sec.gov</U>. Copies of the documents filed with the
SEC by CVS Health are available free of charge within the Investors section of CVS Health&#146;s Web site at http://www.cvshealth.com/investors or by contacting CVS Health&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">800-201-0938.</FONT></FONT> Copies of the documents filed with the SEC by Aetna are available free of charge on Aetna&#146;s internet website at http://www.Aetna.com or by contacting Aetna&#146;s Investor Relations
Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">860-273-0896.</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies
in connection with the proposed transaction. Information about the directors and executive officers of CVS Health is set forth in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, which
was filed with the SEC on February&nbsp;9, 2017, its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on March&nbsp;31, 2017, and certain of its Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K.</FONT> Information about the directors and executive officers of Aetna is set forth in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, which was
filed with the SEC on February&nbsp;17, 2017, its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April&nbsp;7, 2017, and certain of its Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K.</FONT> Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the definitive joint
proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding
Forward-Looking&nbsp;Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 (the &#147;Reform Act&#148;) provides a safe harbor for
forward-looking statements made by or on behalf of CVS Health or Aetna. This Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> may contain forward-looking statements within the meaning of the Reform Act. You can generally identify
forward-looking statements by the use of forward-looking terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;evaluate,&#148; &#147;expect,&#148;
&#147;explore,&#148; &#147;forecast,&#148; &#147;guidance,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;probable,&#148;
&#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;view,&#148; or &#147;will,&#148; or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond CVS Health&#146;s and Aetna&#146;s control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> regarding CVS Health and
Aetna that are forward-looking, including CVS Health&#146;s and Aetna&#146;s projections as to the closing date for the pending acquisition of Aetna (the &#147;transaction&#148;), the extent of, and the time necessary to obtain, the regulatory
approvals required for the transaction, the anticipated benefits of the transaction, the impact of the transaction on CVS Health&#146;s and Aetna&#146;s businesses, the expected terms and scope of the expected financing for the transaction, the
ownership percentages of CVS Health&#146;s common stock of CVS Health stockholders and Aetna shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health&#146;s expectations
regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS Health&#146;s and Aetna&#146;s respective share repurchase programs and ability and intent to declare future dividend payments, the number of
prescriptions used by people served by the combined companies&#146; pharmacy benefit business, the synergies from the transaction, and CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s future operating results, are based on CVS
Health&#146;s and Aetna&#146;s managements&#146; estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the
combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> relating to
pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements
of CVS Health and Aetna. Important risk factors related to the transaction could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to
consummate the proposed transaction; the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the
closing of the proposed transaction may not be satisfied; the outcome of litigation related to the transaction; the ability to achieve the synergies and value creation contemplated; CVS Health&#146;s ability to promptly and effectively integrate
Aetna&#146;s businesses; and the diversion of and attention of management of both CVS Health and Aetna on transaction-related issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> may contain forward-looking statements regarding CVS Health&#146;s or Aetna&#146;s respective businesses, financial condition and results of operations. These forward-looking
statements also involve risks, uncertainties and assumptions, some of which may not be presently known to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS Health&#146;s or Aetna&#146;s actual results to differ
materially from those expressed in the forward-looking statements, adversely impact their respective businesses, CVS Health&#146;s ability to complete the transaction and/or CVS Health&#146;s ability to realize the expected benefits from the
transaction. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health&#146;s ability to successfully complete the transaction
and/or realize the expected benefits from the transaction. Additional information concerning these risks, uncertainties and assumptions can be found in CVS Health&#146;s and Aetna&#146;s respective filings with the SEC, including the risk factors
discussed in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and Aetna&#146;s most recent Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated by their Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> and future filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on CVS Health&#146;s and
Aetna&#146;s forward-looking statements. These forward-looking statements are and will be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of
such statements. Neither CVS Health nor Aetna assumes any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">CVS HEALTH CORPORATION</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Colleen M. McIntosh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Colleen M. McIntosh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President and</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Corporate
Secretary</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dated:&nbsp;February 9, 2018</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g451547img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g451547img001.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M-:W%M-;WD,Q@EMI(F$J2AMIC*8R&SQCKFOS_ #"KC\-BI-R=I;6VMY>9_=G
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M^(^NZE\-=;UFWFATR^">6UE?K^Y3&T'$;N$W?],R:^J_CS^WK\,O TOA^W\
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G86^M:W;^(Y-1NM):\BU^\3-E'!)(EML$NP1JYW!<8!Y'-%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
